ISDA

Deposition Date 2009-08-03

Release Date 2010-02-23

Last Version Date 2024-05-08

Entry Detail

PDB ID:

2WPA

Keywords:

CELL CYCLE

Title:

Optimisation of 6,6-Dimethyl Pyrrolo 3,4-c pyrazoles: Identification of PHA-793887, a Potent CDK Inhibitor Suitable for Intravenous Dosing

Biological Source:

Source Organism:

HOMO SAPIENS (Taxon ID: 9606)

Host Organism:

TRICHOPLUSIA NI

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.51 Å

R-Value Free:

0.26

R-Value Work:

0.22

R-Value Observed:

0.22

Space Group:

P 62 2 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:CELL DIVISION PROTEIN KINASE 2
Gene (Uniprot):CDK2
Chain IDs:A, C
Chain Length:309
Number of Molecules:2
Biological Source:HOMO SAPIENS

UniProt ID:P24941 Pfam ID:PF00069 EC:2.7.11.22

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:CYCLIN A2
Gene (Uniprot):CCNA2
Chain IDs:B, D
Chain Length:265
Number of Molecules:2
Biological Source:HOMO SAPIENS

UniProt ID:P20248 Pfam ID:PF00134, PF02984

Ligand Molecules

889

SO4

Primary Citation

Optimization of 6,6-Dimethyl Pyrrolo[3,4-C]Pyrazoles: Identification of Pha-793887, a Potent Cdk Inhibitor Suitable for Intravenous Dosing.

Brasca, M.G, Albanese, C, Alzani, R, Amici, R, Avanzi, N, Ballinari, D, Bischoff, J, Borghi, D, Casale, E, Croci, V, Fiorentini, F, Isacchi, A, Mercurio, C, Nesi, M, Orsini, P, Pastori, W, Pesenti, E, Pevarello, P, Roussel, P, Varasi, M, Volpi, D, Vulpetti, A, Ciomei, M.Show

Bioorg.Med.Chem. 18 1844 ? (2010)

PMID: 20153204 DOI: 10.1016/J.BMC.2010.01.042

Abstact

We have recently reported CDK inhibitors based on the 6-substituted pyrrolo[3,4-c]pyrazole core structure. Improvement of inhibitory potency against multiple CDKs, antiproliferative activity against cancer cell lines and optimization of the physico-chemical properties led to the identification of highly potent compounds. Compound 31 (PHA-793887) showed good efficacy in the human ovarian A2780, colon HCT-116 and pancreatic BX-PC3 carcinoma xenograft models and was well tolerated upon daily treatments by iv administration. It was identified as a drug candidate for clinical evaluation in patients with solid tumors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures